The bovine tuberculosis diagnosis market is expected to register a CAGR of 4.2% over the forecast period.
The COVID-19 pandemic had a substantial impact on the bovine tuberculosis diagnosis market. Lockdown declarations in several nations, as well as the corresponding limited access to and closure of veterinary facilities, are mostly responsible for declining market growth. Due to the forced cancellation and reduction of veterinarian appointments, the pandemic made it harder for pet owners to receive proper veterinary diagnosis and treatment. For instance, according to a February 2022 article released by the Taylor & Francis Group, at the onset of the pandemic, around 70% of veterinary clinics in Canada and the United States closed their doors to the public to curb the spread of the virus to veterinary personnel as well as nonhuman animal patients in the clinic. However, the government and market players have taken various initiatives to continue their eradication programs during the pandemic. For instance, according to the Michigan Department of Agriculture and Rural Development (MDARD), activities under the Bovine Tuberculosis Eradication Program, such as TB testing, continued during the pandemic while following precautions to curb disease spread.
Furthermore, the increasing cattle population, coupled with increasing consumption of animal products, the increasing prevalence of zoonotic diseases, and supportive regulations and programs implemented by governments, are the factors driving the growth of the bovine tuberculosis diagnostics market over the forecast period.
Supportive regulations and programs implemented by governments are major factors driving the demand for the bovine tuberculosis diagnosis market. For instance, in May 2021, the United Kingdom’s Department of Environment, Food, and Rural Affairs launched a proposal to help eradicate bovine tuberculosis in England through strategic priorities for a secure, productive, and sustainable agriculture system, a productive and sustainable food and drink industry, enhanced animal health and welfare, and plant health, as well as the government’s overarching objective of supporting economic growth.
Moreover, the increasing prevalence of zoonotic diseases is also one of the factors driving the bovine tuberculosis diagnosis market. For example, the World Health Organization stated in May 2021 that identifying capacity gaps as well as agreement on good practices to prevent and prepare for zoonotic outbreaks, and the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health had launched a guide for countries on taking a one-health approach to addressing zoonotic diseases.
In addition, new launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For Instance, In February 2020, IDVET launched a new bovine tuberculosis qPCR test. It amplifies a target sequence in the Mycobacterium tuberculosis complex's genome (MTC). It is a qualitative duplex test that amplifies both the target DNA and an external internal control at the same time. It may be used to test lymph nodes and peripheral tissues from cattle, sheep, goats, deer, and badgers. Therefore, owing to the aforementioned factors, it is anticipated that the studied market will witness growth over the analysis period.
Moreover, the rising focus on developing technologically advanced diagnostic devices and increasing product launches are also contributing to market growth. For instance, in July 2020, Mylab launched a machine to automate molecular diagnostic tests, a compact bench-top machine that will automate lab processes from sample handling to preparing reverse transcription polymerase chain reaction (PCR)-ready tubes.
Furthermore, government and private collaborations for the development of novel molecular diagnostics are expected to drive the growth of the studied segment over the forecast period. For instance, in August 2022, 3EO Health licensed Wyss Institute technology from Harvard and announced that it is currently developing at-home molecular testing with PCR-grade sensitivity and antigen test-level cost. Therefore, the Molecular Diagnostic Tests segment is expected to witness significant growth over the forecast period due to the above-mentioned factors.
Another factor driving the growth of the market for bovine tuberculosis diagnosis is the increase in the number of veterinary clinics in various countries that are staffed by veterinarians who are qualified and licensed. For instance, in October 2020, the National Tuberculosis Eradication Program, conducted by the U.S. Department of Agriculture's Animal and Plant Health Inspection Service, state animal health agencies, and U.S. livestock producers, will have nearly eradicated bovine TB from the nation's livestock population since the program's inception in 1917. The presence of bovine TB in humans has also been reduced because of several factors, including the eradication program and the pasteurization of milk.
Furthermore, strategic initiatives by government and private companies, as well as the rising prevalence of bovine tuberculosis diseases, are driving growth in the North American region.For instance, in March 2022, according to the United States embassy and consulates in Mexico, the United States ambassador launched a new five-year project in California to vaccinate cattle against bovine tuberculosis to protect dairy cows, which have adverse economic consequences for the dairy producers as the disease renders cattle less productive.
Additionally, increasing research and development activities around veterinary diagnostics technologies in the region is likely to boost market growth. The advanced strategies initiated by animal health key players to identify novel bovine tuberculosis diagnostic indicators are further enhancing the opportunity for segment growth. The ICMR, for example, launched a study into human-to-cattle TB infections in July 2022, and the prevalence of bovine TB in household cattle across the country since reverse zoonosis is an alarming development. Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.
This product will be delivered within 2 business days.
The COVID-19 pandemic had a substantial impact on the bovine tuberculosis diagnosis market. Lockdown declarations in several nations, as well as the corresponding limited access to and closure of veterinary facilities, are mostly responsible for declining market growth. Due to the forced cancellation and reduction of veterinarian appointments, the pandemic made it harder for pet owners to receive proper veterinary diagnosis and treatment. For instance, according to a February 2022 article released by the Taylor & Francis Group, at the onset of the pandemic, around 70% of veterinary clinics in Canada and the United States closed their doors to the public to curb the spread of the virus to veterinary personnel as well as nonhuman animal patients in the clinic. However, the government and market players have taken various initiatives to continue their eradication programs during the pandemic. For instance, according to the Michigan Department of Agriculture and Rural Development (MDARD), activities under the Bovine Tuberculosis Eradication Program, such as TB testing, continued during the pandemic while following precautions to curb disease spread.
Furthermore, the increasing cattle population, coupled with increasing consumption of animal products, the increasing prevalence of zoonotic diseases, and supportive regulations and programs implemented by governments, are the factors driving the growth of the bovine tuberculosis diagnostics market over the forecast period.
Supportive regulations and programs implemented by governments are major factors driving the demand for the bovine tuberculosis diagnosis market. For instance, in May 2021, the United Kingdom’s Department of Environment, Food, and Rural Affairs launched a proposal to help eradicate bovine tuberculosis in England through strategic priorities for a secure, productive, and sustainable agriculture system, a productive and sustainable food and drink industry, enhanced animal health and welfare, and plant health, as well as the government’s overarching objective of supporting economic growth.
Moreover, the increasing prevalence of zoonotic diseases is also one of the factors driving the bovine tuberculosis diagnosis market. For example, the World Health Organization stated in May 2021 that identifying capacity gaps as well as agreement on good practices to prevent and prepare for zoonotic outbreaks, and the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health had launched a guide for countries on taking a one-health approach to addressing zoonotic diseases.
In addition, new launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For Instance, In February 2020, IDVET launched a new bovine tuberculosis qPCR test. It amplifies a target sequence in the Mycobacterium tuberculosis complex's genome (MTC). It is a qualitative duplex test that amplifies both the target DNA and an external internal control at the same time. It may be used to test lymph nodes and peripheral tissues from cattle, sheep, goats, deer, and badgers. Therefore, owing to the aforementioned factors, it is anticipated that the studied market will witness growth over the analysis period.
Key Market Trends
The Molecular Diagnostic Tests segment is Expected to Witness Growth Over the Forecast Period
The molecular diagnostics tests segment has recently expanded due to molecular methodologies offering numerous advantages, such as usefulness in the identification of target molecules and, in comparison to standard traditional culture methods, faster turnaround times from receipt to result in reporting, as well as a broader range of applications.Moreover, the rising focus on developing technologically advanced diagnostic devices and increasing product launches are also contributing to market growth. For instance, in July 2020, Mylab launched a machine to automate molecular diagnostic tests, a compact bench-top machine that will automate lab processes from sample handling to preparing reverse transcription polymerase chain reaction (PCR)-ready tubes.
Furthermore, government and private collaborations for the development of novel molecular diagnostics are expected to drive the growth of the studied segment over the forecast period. For instance, in August 2022, 3EO Health licensed Wyss Institute technology from Harvard and announced that it is currently developing at-home molecular testing with PCR-grade sensitivity and antigen test-level cost. Therefore, the Molecular Diagnostic Tests segment is expected to witness significant growth over the forecast period due to the above-mentioned factors.
North America is Expected to Dominate the Bovine Tuberculosis Diagnosis Market Over the Forecast Period
North America held a notable market share of the bovine tuberculosis diagnosis market during the forecast period. The high share of the region is due to the significant presence of key players, the implementation of numerous tactics developed by leading corporations to broaden their market reach, as well as expanding research activity, diagnostic rates, the animal population, and veterinary care costs.Another factor driving the growth of the market for bovine tuberculosis diagnosis is the increase in the number of veterinary clinics in various countries that are staffed by veterinarians who are qualified and licensed. For instance, in October 2020, the National Tuberculosis Eradication Program, conducted by the U.S. Department of Agriculture's Animal and Plant Health Inspection Service, state animal health agencies, and U.S. livestock producers, will have nearly eradicated bovine TB from the nation's livestock population since the program's inception in 1917. The presence of bovine TB in humans has also been reduced because of several factors, including the eradication program and the pasteurization of milk.
Furthermore, strategic initiatives by government and private companies, as well as the rising prevalence of bovine tuberculosis diseases, are driving growth in the North American region.For instance, in March 2022, according to the United States embassy and consulates in Mexico, the United States ambassador launched a new five-year project in California to vaccinate cattle against bovine tuberculosis to protect dairy cows, which have adverse economic consequences for the dairy producers as the disease renders cattle less productive.
Additionally, increasing research and development activities around veterinary diagnostics technologies in the region is likely to boost market growth. The advanced strategies initiated by animal health key players to identify novel bovine tuberculosis diagnostic indicators are further enhancing the opportunity for segment growth. The ICMR, for example, launched a study into human-to-cattle TB infections in July 2022, and the prevalence of bovine TB in household cattle across the country since reverse zoonosis is an alarming development. Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.
Competitive Landscape
The market for bovine tuberculosis diagnosis is moderately competitive. Leading players deploy numerous strategic initiatives that include competitive pricing strategies, partnerships, product expansion, sales and marketing initiatives, and mergers and acquisitions. IDEXX laboratories, PDB Biotech Ltd., Zoetis, IDVET, Thermo Fisher Scientific Inc., Abbott Laboratories, Enfer Group, Asurequality Australia Pty Ltd, Bio-Rad Laboratories Inc., and Bionote are among the key players in the markets.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- IDEXX Laboratories
- PBD Biotech Ltd
- Zoetis
- IDvet
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Enfer Group
- AsureQuality Australia Pty Ltd
- Bio-Rad Laboratories Inc
- Bionote
Methodology
LOADING...